Akebia Therapeutics (AKBA) Stock’s Ratio Analysis:
The Company was able to keep Return on assets (ROA) at -25.40% in the trailing twelve month. ROA shows that how profitable a company is relative to its total assets. ROA gives an idea as to how efficient management is at using its assets to generate earnings. Calculated by dividing a company’s annual earnings by its total assets, ROA is displayed as a percentage. The Company generated Return on equity (ROE) -50.30% over the last twelve months. ROE is a measure of a corporation’s profitability that reveals how much profit a company generates with the money shareholders have invested. Calculated as Net Income / Shareholder’s Equity. It has kept Return on investment (ROI) at -23.00%. ROI is a financial ratio intended to measure the benefit obtained from an investment. Time is usually of the essence in this measurement because it takes time for an investment to realize a benefit.
Long Term Debt/Equity ratio was recorded at 0. This measures a company’s financial leverage calculated by dividing its long term debt by stockholders’ equity. It indicates what proportion of equity and debt the company is using to finance its assets. On the other side the debt to equity ratio is 0.02. Its current ratio is 1.8. Current Ratio is a liquidity ratio that measures a company’s ability to pay short-term obligations. Quick Ratio of 1.3 is an indicator of a company’s short-term liquidity. The quick ratio measures a company’s ability to meet its short-term obligations with its most liquid assets. The higher the quick ratio, the better the position of the company.
Let’s consider Akebia Therapeutics (AKBA) stock move that changed on Tuesday Dated APRIL 16, 2019. 895191 shares changed at hands in last session versus to an average volume of 1175.81K shares. Akebia Therapeutics (AKBA) stock ended at $7.13 by scoring 1.57%. It has 114.49M outstanding shares and 107.49M shares have been floated in market exchange. The stock institutional ownership included 69.70% while insider ownership remained 1.10%. The net percent change held by Institutional Investors has seen a change of 0.46% over last three month period. The net percent change kept by insiders has seen a change of 0.00% over last six month period.
Stock’s Price Fluctuations & Volatility:
The stock price registered volatility 5.18% in past week and volatility was at 6.25% over a last month. Historical volatility refers to the price fluctuations exhibited by the underlying asset (such as stock) over time. A security with high volatility has bigger fluctuations in price compared to a security with low volatility. The more quickly a price changes up and down, the more volatile it is. As such, volatility is often used as a measure of risk.
The stock’s Average True Range for 14 days was 0.48. ATR measures volatility, taking into account any gaps in the price movement. High ATR indicates increased volatility. A low ATR value indicates a series of periods with small ranges. Company’s beta coefficient stands at 1.46. Beta factors measures the amount of market risk associated with market trade. Presently, (AKBA) has a RSI reading of 43.76.
Akebia Therapeutics (AKBA) Stock’s Moving Average & Performance Analysis:
The stock showed weekly performance of -4.42% and it maintained for the month at -12.73%. Likewise the performance for the quarter was recorded as 16.12% and for the year it was -28.34%. The stock showed -18.23% performance during last 6-months. The YTD performance remained at 28.93%. This stock traded upward toward its 52 week low with 37.12% and -38.53% negative from its 52 week high price. The stock price is moving down from its 20 days moving average with -9.30% and it is trading down from 50 days moving average with -3.09%. The stock price is moving along negative drift from its 200 days moving average with -9.48%.